Cumulus Neuroscience ExpandsDevelopment Support of NovelPrecision CNS Therapeutics
Growing Biopharma Partnerships Underscore Company Commitment to Accelerate Neuroscience Precision MedicineInnovation; New Boston-Area Offices Establish U.S. Presence
BELFAST, Northern Ireland and CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; TheCompany), a global digital health company focused on advancing neuroscience clinical trials and patient care throughimproved data, today announced the establishment of new Cumulus offices in the Boston area to support its expandingpartnerships with biopharma innovators. The new Cambridge Innovation Center (CIC) location, in the leading life scienceshub, will help foster existing and future collaborations across diverse aspects of Central Nervous System (CNS) innovation, anddeepen the company’s presence in North America.
“Cumulus is driven to become the preferred precision CNS drug development partner for biopharma innovators developingcutting-edge therapeutics, and our presence in Cambridge serves to support both existing and expanding collaborations –which, we hope, will ultimately advance the CNS ecosystem for the benefit of patients,” said Aman Bhatti, MD, CEO, CumulusNeuroscience. “There remains an urgent unmet need facing millions of patients and families navigating neuropsychiatric andneurodegenerative conditions, and we are committed to accelerating change for these patients, as well as broadening theimpact Cumulus aspires to make for the biopharma sector.”
The establishment of the Cumulus Boston-area presence will help strengthen the Company’s collaborations withMassachusetts-based companies, including Sunovion Pharmaceuticals. “Sunovion is committed to innovative approaches inCNS drug development and the collaboration with Cumulus is focused on therapies to address serious neuropsychiatricconditions,” said Kenneth Koblan, Ph.D., Chief Scientific Officer of Sunovion.
Cumulus supports greater precision in clinical trials through its first-in-class neuro-assessment platform, which improves thecharacterization of a drug’s effect on the brain and provides more frequent, objective assessments – accelerating go/no-godecisions for development teams. The Cumulus EEG synced digital platform utilizes a range of validated cognitive andbehavioral tasks precisely synchronized to a dry-sensor EEG for use in-clinic or in unsupervised (at-home/remote)environments, allowing for increased ease-of-use for patients and caregivers. By enabling remote monitoring of patientsacross multiple domains of brain function, biopharma innovators are able to sample a broad spectrum of CNS domainmeasurements, from specific disease symptoms to functional neurophysiology, in order to understand the drug effect ofvarying doses on cognition, mood, memory, and language, and to match the right patient to the right therapy.
Cumulus anticipates establishing additional clinical-stage collaborations in the coming year. Its new U.S. location is alignedwith the company’s recent executive leadership team expansion. To learn more, visit www.cumulusneuro.com.
About Cumulus Neuroscience
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system(CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based,multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinicaltrials and patient care, beginning with dementia and Alzheimer’s disease.
Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combinespatented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical datarepeated over time, across multiple behavioral and physiological domains in the patient’s home – all by a certified medicaldevice package. Together with machine learning (ML) analytics and an extensive real-world database of annotated,longitudinal, matched data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the bestand most cost-effective assessment of CNS treatment outcomes.
The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, anda world-class Scientific and Technical Advisory Board.
